Clinical Trials | June 02, 2026
Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The therapy also delivered significant improvements in key liver enzyme markers
This marks one of the most closely watched oncology readouts at this year’s medical congress
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The decision marks a key step in the centralized EU review process
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The development comes as stroke remains one of the world’s biggest health threats
Baxfendy works in a fundamentally different way from current therapies
Nearly one in five women worldwide are now living with obesity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
